Head-To-Head Comparison: Haemonetics Corporation (NYSE:HAE) vs. Its Peers

Haemonetics Corporation (NYSE: HAE) is one of 84 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its peers? We will compare Haemonetics Corporation to similar businesses based on the strength of its dividends, risk, valuation, institutional ownership, earnings, profitability and analyst recommendations.

Institutional & Insider Ownership

66.2% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 1.2% of Haemonetics Corporation shares are owned by company insiders. Comparatively, 11.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.


This table compares Haemonetics Corporation and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Haemonetics Corporation 0.48% 11.07% 6.54%
Haemonetics Corporation Competitors -126.58% -36.58% -10.02%

Analyst Ratings

This is a breakdown of current ratings and price targets for Haemonetics Corporation and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Haemonetics Corporation 0 3 3 0 2.50
Haemonetics Corporation Competitors 180 1144 2503 89 2.64

Haemonetics Corporation currently has a consensus price target of $44.60, suggesting a potential downside of 6.85%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 7.22%. Given Haemonetics Corporation’s peers stronger consensus rating and higher possible upside, analysts clearly believe Haemonetics Corporation has less favorable growth aspects than its peers.

Earnings and Valuation

This table compares Haemonetics Corporation and its peers gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Haemonetics Corporation $887.11 million $164.54 million 598.57
Haemonetics Corporation Competitors $827.23 million $159.50 million 41.26

Haemonetics Corporation has higher revenue and earnings than its peers. Haemonetics Corporation is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Haemonetics Corporation has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Haemonetics Corporation’s peers have a beta of 1.06, meaning that their average stock price is 6% more volatile than the S&P 500.


Haemonetics Corporation peers beat Haemonetics Corporation on 8 of the 13 factors compared.

About Haemonetics Corporation

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply